Therapeutic potential of the human gastrointestinal microbiome

Drug Development Research

Volumn 74, Issue 6, 2013, Pages 385-392

  Borody, Thomas J ^a   Peattie, Debra ^b   Campbell, Jordana ^a  

^a Centre for Digestive Diseases   (Australia)

^b Pleiades Advisors   (United States)

Author keywords

Clostridium difficile; fecal microbiota transplantation; microbiome; microbiota; probiotics

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIOCIN; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VACCINE; VITAMIN; VP 202621;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTISM; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIUM; BACTERIUM CULTURE; CLOSTRIDIUM; CLOSTRIDIUM BOLTEAE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG POTENCY; ENTEROTOXIGENIC ESCHERICHIA COLI DIARRHEA; ESCHERICHIA COLI INFECTION; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HOMEOSTASIS; HUMAN; INTESTINE FLORA; METABOLITE; MICROBIOME; NONHUMAN; TRANSPLANTATION; ULCERATIVE COLITIS;

EID: 84883867628     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21093     Document Type: Article

References (61)

1. Ackermann HW,. 2011. On an invisible microbe antagonistic to dysentery bacilli. Note by M.F. d'Herelle, presented by M. Roux. Comptes Rendus Academie des Sciences 1917 165:373-5. Bacteriophage 1: 3-5.
2. Aroniadis OC, Brandt LJ,. 2013. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 29: 79-84.
3. Baier W, Sedelmeier EA, Bessler WG,. 1997. Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Arzneimittelforschung 47: 980-985.
4. Bakkal S, Robinson SM, Riley MA,. 2012. Bacteriocins of aquatic microorganisms and their potential applications in the seafood industry. In: Health and Environment in Aquaculture, Chap 12., Carvalho ED, editor. http://www.intechopen.com/books/healthand-environment-in-aquaculture/ bacteriocins-of-aquatic-microorganisms-and-their-potential-applications-in-the- seafood-industry.
5. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS,. 2002. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 19: 451-456.
6. Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Shulmann CC,. 2005. A long-term, multi-center, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 47: 542-548.
7. Berer K, Mues M, Koutrolos M, Rasbi ZA, Johner C, Wekerle H, Krishnamoorthy G,. 2011. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479: 538-542.
8. Bessler WG, vor dem Esche U, Zgaga-Griesz A, Ataullakhanov R,. 2010. Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo. Arzneimittelforschung 60: 324-329.
9. Black RE,. 1990. Epidemiology of travelers' diarrhoea and relative importance of various pathogens. Clin Infect Dis 12 (Supp 1): S73-S79.
10. Borody TJ, Khoruts A,. 2012. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9: 88-96.
11. Burke C, Steinberg P, Rusch D, Kjelleberg S, Thomas T,. 2011. Bacterial community assembly based on functional genes rather than species. Proc Natl Acad Sci U S A 108: 14288-14293.
12. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB,. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhoea. J Infect Dis 197: 435-438.
13. Cotter PD, Ross RP, Hill C,. 2013. Bacteriocins-a viable alternative to antibiotics? Nat Rev Microbiol 11: 95-105.
14. Davies J,. 1994. Inactivation of antibiotics and the dissemination of resistance genes. Science 264: 375-382.
15. Finegold SM,. 2011. State of the art; microbiology in health and disease. Intestinal bacterial flora in autism. Anaerobe 17: 367-368.
16. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, et al. 2002. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 35 (Suppl 1): S6-S16.
17. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D, et al. 2010. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16: 444-453.
18. Fleckenstein JM, Hardwidge PR, Munson GP, Rasko DA, Sommerfelt H, Steinsland H,. 2010. Molecular mechanisms of enterotoxigenic Escherichia coli infection. Microbes Infect 12: 89-98.
19. Flint HJ, O'Toole PW, Walker AW,. 2010. Special issue: the human intestinal microbiota. Microbiology 156: 3203-3204.
20. Floch MH,. 2010. Fecal bacteriotherapy, fecal transplant and the microbiome. J Clin Gastroenterol 44: 567-570.
21. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE,. 2006. Metagenomic analysis of the human distal gut microbiome. Science 312: 1355-1359.
22. Grabe M, Bjerklund-Johansen TE, Botto H, Cek M, Naber KG, Tenke P, Wagenlehner F,. 2013. Guidelines on urological infections. Eur Assoc. Urol. p 7-111. http://www.uroweb.org/gls/pdf/Urological%20Infections%202010.pdf.
23. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A,. 2010. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 44: 551-561.
24. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A,. 2012. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107: 761-767.
25. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ,. 2013. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4: 1-11.
26. Hawkes CH, Del Tredici K, Braak H,. 2009. Parkinson's disease: the dual hit theory revisited. N Y Acad Sci 1170: 615-622.
27. Inagaki H, Suzuki T, Nomoto K, Yoshikai Y,. 1996. Increased susceptibility to primary infection with Listeria monocytogenes in germfree mice may be due to a lack of accumulation of L-selectin+ CD44+ T cells in sites of inflammation. Infect Immunity 64: 3280-3287.
28. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY,. 2009. National point prevalence of Clostridium difficile in US health care facility inpatients. Am J Infect Control 37: 263-270.
29. Jones E, Salin V, Williams GW,. 2005. Nisin and the market for commercial bacteriocins. Texas Agribusiness Market Research Center Consumer Report. http://ageconsearch.umn.edu/bitstream/90779/2/CP%2001%2005%20Nisin%20Report.pdf.
30. Jorup-Rönström C, Håkanson A, Sandell S, Edvinsson O, Midtvedt T, Persson AK, Norin E,. 2012. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 47: 548-552.
31. Katz S,. 2010. E. coli Nissle 1917 in the treatment of inflammatory bowel disease. Pract Gastroenterol 60: 11-19. http://www.practicalgastro.com/pdf/ March10/SchultzArticle.pdf.
32. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ,. 2010. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44: 354-360.
33. Konturek PC, Sliwowski Z, Koziel J, Ptak-Belowska A, Burnat G, Brzozowski T, Konturek SJ,. 2009. Probiotic bacteria Escherichia coli strain Nissle 1917 attentuates acute gastric lesions induced by stress. J Physiol Pharmacol 60 (Suppl 6): 41-48.
34. Kruis W, Chrubasik S, Stange C, Schulze J,. 2012. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 27: 467-474.
35. Lederberg J,. 1996. Smaller fleas. ad infinitum: therapeutic bacteriophage redux. Proc Natl Acad Sci U S A 93: 3167-3168.
36. Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GD, Lewis JD, Bushman FD,. 2011. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 21: 1616-1625.
37. Musso G, Gambino R, Cassader M,. 2011. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Ann Rev Med 62: 361-380.
38. Nilsson AI, Koskiniemi S, Eriksson S, Kugelberg E, Hinton JCD, Andersson DI,. 2005. Bacterial genome size reduction by experimental evolution. Proc Natl Acad Sci U S A 102: 12112-12116.
39. Nissle A,. 1918. Die antagonistische behandlung chronischer darmstörungen mit colibakterien. Medizinische Klinik 2: 29-33.
40. Olle B,. 2013. Medicines from microbiota. Nature 31: 309-315.
41. Parks BW, Nam E, Org E, Kostem E, Norheim F, Hui ST, Pan C, Civelek M, Rau CD, Bennett BJ, et al. 2013. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab 17: 141-152.
42. Parracho HMRT, Bingham MO, Gibson GR, McCartney AL,. 2005. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 54: 987-991.
43. Pequegnat B, Sagermann M, Valliani M, Toh M, Chow H, Allen-Vercoe E, Monteiro MA,. 2013. A vaccine and diagnostic target for Clostridium bolteae, an autism-associated bacterium. Vaccine 31: 2787-2790.
44. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E,. 2013. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePOOPulating" the gut. Microbiome 1: 3.
45. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59-65.
46. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al. 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490: 55-60.
47. Reyes A, Haynes M, Hanson M, Angly FE, Heath AC, Rohwer F, Gordon JI,. 2010. Viruses in the fecal microbiota of monozygotic twins and their mothers. Nature 466: 334-338.
48. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC,. 2009. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 144: 433-439.
49. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Vaisanen ML, Nelson MN, Wexler HM,. 2000. Short term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 15: 429-435.
50. Saxelin M, Lassig A, Karjalainen H, Tynkkynen S, Surakka A, Vapaatalo H, Jarvenpaa S, Korpela R, Mutanen M, Hatakka K,. 2010. Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt or cheese. Int J Food Microbiol 144: 293-300.
51. Schultz M,. 2008. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 14: 1012-1018.
52. Silva M, Jacobus NV, Deneke C, Gorbach SL,. 1987. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 31: 1231-1233.
53. Smith K, McCoy KD, Macpherson AJ,. 2007. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Sem Immunol 19: 59-69.
54. Stewart EJ,. 2012. Growing unculturable bacteria. J Bacteriol 194: 4151-4160.
55. Svennerholm AM, Lundgren A,. 2012. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines 11: 495-507.
56. Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PG,. 2012. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 25: 255-257.
57. Tvede M, Rask-Madsen J,. 1989. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1: 1156-1160.
58. Van Pham T, Kreis B, Corradin-Betz S, Bauer J, Mauel J,. 1990. Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J Biol Response Mod 9: 231-240.
59. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN,. 2012. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56: 5224-5229.
60. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A,. 2013. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. doi: 10.1097/MCG.0b013e31829004ae. [published ahead of print].
61. Williams BL, Hornig M, Parekh T, Lipkin WI,. 2012. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio 3: e00261-e00211.